| 000 | 00000nam 2200000za 4500 |
| 001 | 9.859119 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107160157 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180716s2018 onca o f000 0 eng d |
|---|
| 020 | |z9780660086385 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-146/2017E-PDF|zNR16146/2017E |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aPartnering for impact |h[electronic resource] : |bHuman Health Therapeutics. |
|---|
| 246 | 30|aHuman Health Therapeutics |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[12] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Partenariats à impact : Thérapeutiques en santé humaine. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aThe catalogue number (NR16146/2017E) and ISBN (978-0-660-08638-5) for the print edition have been copied in this electronic publication. |
|---|
| 520 | |a"The National Research Council (NRC) is the Government of Canada’s premier organization for research and development. Working with clients and partners, we provide innovation support, strategic research, scientific and technical services. NRC’s Human Health Therapeutics (HHT) portfolio works hand in hand with industry to help firms achieve success and save costs. As an R&D partner of choice, NRC de-risks critical steps in the development of biologics and vaccines. We add value to partners’ products and accelerate their progress to market by overcoming challenges all along the value chain"--P. [4]. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 692 | 07|2gccst|aBiological products |
|---|
| 692 | 07|2gccst|aResearch and development |
|---|
| 775 | 08|tPartenariats à impact |w(CaOODSP)9.859120 |
|---|
| 856 | 40|qPDF|s1.71 MB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-146-2017-eng.pdf |
|---|